Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ADCT

ADC Therapeutics

ADCT Lead: Approved ★ Read the deep dive → 4 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $219M (Jun 30, 2026) ↓ 4 verdicts ↓ 4 timing quotes ↓
Oncology Protein

Market cap $202M 127.7M shares (10-Q, Aug 3, 2026) × $1.58 close Nov 6, 2026

Most recent annual filing: 2026-03-10

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. ZYNLONTA + glofitamab toplineDec 2026ZYNLONTA + glofitamab topline, Dec 2026, thesis-defining
  2. ZYNLONTA monotherapy MZL readoutDec 2026ZYNLONTA monotherapy MZL readout, Dec 2026, material
  3. LOTIS-7, LOTIS-5, MCL, WM, MZLDec 12–14, 2026LOTIS-7, LOTIS-5, MCL, WM, MZL, Dec 12–14, 2026, routine
  4. ZYNLONTA corporate update1H 2027ZYNLONTA corporate update, 1H 2027, notable
  5. ZYNLONTA + rituximab FL readout2Q 2027ZYNLONTA + rituximab FL readout, 2Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Capital (as filed)

Cash
$219M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$11.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$189M cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on ADC Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-10 Watch ADC Therapeutics (ADCT) — Scientific Deep Dive for ZYNLONTA and the CD19 ADC Pipeline Confirmed-PFS 3L+ floor and LOTIS-7 optionality keep it from being a PASS, but flat OS, fatal-tox signal, STARGLO regulatory precedent, and ~$420M capital stack against $167M equity keep it off the buy list until Q4 2026 LOTIS-7 data and sBLA path resolve.
  2. 2026-08-14 Avoid UPDATE: ADC Therapeutics (ADCT) - The Floor Just Got a Trapdoor FDA raised substantial concerns about LOTIS-5's benefit-risk and the verification of clinical benefit, putting the 3L+ accelerated approval floor formally in play and turning this into a single-asset regulatory binary with leverage.
  3. 2026-10-09 Watch UPDATE: ADC Therapeutics (ADCT) - The Capital Stack Gets Rebuilt An $86.6M PIPE led by Bain, $70M loan paydown, and elimination of the HCR change-of-control toll largely dismantle the leveraged-binary setup that drove the August downgrade, though the 3L+ label remains contested and dilution has already landed.
  4. 2026-11-05 Speculative buy speculative UPDATE: ADC Therapeutics (ADCT) - The Canary Survived the Doubling LOTIS-7 response rates held almost unchanged as n doubled to 97 with 79% 12-month CR durability and a far lower fatal-event rate than LOTIS-5, MZL strengthened to 90.8% two-year PFS, and revenue growth turned volume-driven, justifying a lottery-ticket speculative position ahead of the December ASH oral.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)